<DOC>
	<DOCNO>NCT01772108</DOCNO>
	<brief_summary>This trial randomize study MitraClip device heart failure patient clinically significant functional mitral regurgitation . A hierarchical composite all-cause mortality recurrent heart failure hospitalization hypothesize occur low rate use MitraClip device addition optimal standard medical therapy compare optimal standard care therapy alone .</brief_summary>
	<brief_title>A Randomized Study MitraClip Device Heart Failure Patients With Clinically Significant Functional Mitral Regurgitation</brief_title>
	<detailed_description>This study clinical evaluation safety effectiveness MitraClip System treatment clinically significant functional mitral regurgitation patient chronic heart failure . The objective study safety effectiveness MitraClip System treatment clinically significant functional mitral regurgitation New York Heart Association Functional Class III IV chronic heart failure patient .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Mitral Valve Insufficiency</mesh_term>
	<criteria>Age 18 year 90 year old Clinically significant functional mitral regurgitation ( moderatetosevere severe mitral regurgitation ) , define European Association Echocardiography , within 90 day prior randomization confirm Echocardiography Core Laboratory Assessed investigator optimal standard care therapy heart failure least 4 week dose change heart failure drug ( exception diuretic ) last 2 week immediately prior randomization Documented New York Heart Association Class III Class IV heart failure , despite optimal standard care therapy , within 90 day precede randomization Minimum one document hospitalization ( acute care admission emergency room visit ) heart failure within 12 month precede randomization OR value least 350 pg/mL BNP least 1400 pg/mL NTproBNP optimal medical and/or device management within 90 day precede randomization Left ventricular ejection fraction ( LVEF ) ≥15 % ≤40 % determined transthoracic echocardiogram within 90 day prior randomization confirm Echocardiography Core Laboratory Left ventricular end diastolic diameter ( LVEDD ) ≥55 mm determine transthoracic echocardiogram within 90 day prior randomization confirm Echocardiography Core Laboratory Patient ambulatory able perform 6MWT limit factor ( ) due cardiovascular fitness Subject agree return required postprocedure followup visit The subject inform nature study agree study 's provision , include possibility randomization Control group , provide write informed consent approve respective clinical site 's Ethics Committee Mitral regurgitation primarily due degenerative disease mitral valve apparatus ( Degenerative mitral regurgitation ) , determine transesophageal echocardiography Status 1 heart transplant prior orthotopic heart transplantation Introduction new heart failure drug class within last 4 week prior randomization Cardiovascular hospitalization within last 2 week immediately prior randomization Evidence acute coronary syndrome , transient ischemic attack stroke within 90 day prior randomization Any percutaneous cardiovascular intervention , carotid surgery , cardiovascular surgery atrial fibrillation ablation within 90 day prior randomization Implant rhythm management device ( i.e. , pacemaker , Cardiac Resynchronization Therapy without cardioverterdefibrillator ( CRT CRTD ) , Implantable Cardioverter Defibrillator ( ICD ) within 90 day prior randomization , revision implant rhythm management device within 90 day prior randomization Need cardiovascular surgery Mitral valve surgery consider therapeutic option subject Renal replacement therapy Uncontrolled hypertension ( i.e. , BP &gt; 180 mmHg systolic and/or &gt; 105 mmHg diastolic ) hypotension ( i.e. , BP &lt; 90 mmHg systolic ) Unstable angina pectoris judge investigator , clinically significant uncorrected valvular disease leave ventricular outflow obstruction , obstructive cardiomyopathy , poorly control fast atrial fibrillation flutter , poorly control symptomatic brady tachyarrhythmias 6MWT distance &gt; 450 meter Mitral Valve Area ( MVA ) planimetry &lt; 4.0 cm2 ; MVA planimetry measurable , pressure halftime measurement acceptable ; MVA must confirm Echocardiography Core Laboratory Leaflet anatomy may preclude MitraClip device implantation , proper device position leaflet , sufficient reduction mitral regurgitation may include : Evidence calcification grasp area Presence significant cleave grasp area Lack primary secondary chordal support grasp area Prior mitral valve surgery Coaptation length ≤2 mm Leaflet mobility length &lt; 1 cm Presence IVC filter femoral vein would interfere delivery catheter , ipsilateral deep vein thrombosis ( DVT ) present Contraindication transseptal catheterization Subjects transesophageal echocardiography contraindicate Echocardiographic evidence intracardiac mass , thrombus , vegetation Active endocarditis active rheumatic heart disease leaflet degenerate rheumatic disease ( i.e. , noncompliant , perforate ) Presence follow : Severe aortic stenosis ( aortic valve area &lt; 1.0 cm2 ) severe aortic regurgitation Infiltrative cardiomyopathy ( e.g. , amyloidosis , hemochromatosis , sarcoidosis ) Hypertrophic cardiomyopathy , restrictive cardiomyopathy , constrictive pericarditis , structural heart disease cause heart failure dilate cardiomyopathy either ischemic nonischemic etiology Hemodynamic instability require inotropic support mechanical heart circulatory support Active infection require current antibiotic therapy Known hypersensitivity contraindication procedural medication adequately manage medically Severe right ventricular failure severe tricuspid regurgitation History bleed diathesis coagulopathy subject refuse blood transfusion Pregnant planning pregnancy within next 12 month . Note : Female patient childbearing potential need negative pregnancy test perform within 14 day prior randomization adherent accept method contraception Concurrent medical condition life expectancy le 12 month judgment investigator Currently participate another therapeutic interventional heart failure trial , trial unapproved drug device ( Subjects participate observational study registry may consider eligible ) Subject belongs vulnerable population per investigator 's judgment subject kind disorder compromise his/her ability give write informed consent and/or comply study procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Heart Valve Diseases</keyword>
</DOC>